Zhe Jiang Dayang Biotech Group (003017) Fair Value & Analysis
Basic Materials · CN · Market cap 2.3B CNY
Fair value as of: Jun 25, 2026
Analysis
Zhe Jiang Dayang Biotech Group (003017) currently trades at ¥26.87, while our model-based Fair Value estimate is ¥20.21 — implying the stock looks roughly 24.8% overvalued today. We read business quality at 95/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Zhe Jiang Dayang Biotech Group Co., Ltd. operates as a chemical raw material manufacturing company in China and internationally. The company offers inorganic chemicals, including potassium carbonate and chloride, ammonium chloride, and bicarbonate food and feed additives; industrial grade potassium carbonate and bicarbonate; and agricultural and industrial grade ammonium chloride. It also provides 2-chloro-6-fluorobenzoic acid, fluorobenzaldehyde, and fluorobenzyl chloride. In addition, it offers aminopropionate hydrochloride; enramycin premix; and aniline. Further, it engages in the wholesale and retail of pharmaceutical intermediates; and research and development of industrial enzyme preparations and biological feeds. The company was founded in 1976 and is based in Jiande, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Zhe Jiang Dayang Biotech Group (003017) undervalued?
What is the fair value of 003017?
What is the quality score of 003017?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.